2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3767 Cytoreduction in adolescent and young adult patients with polycythemia vera and essential thrombocythemia: Indications, agent selection, and durability

Sandro Pino-Ascencio, MD, Shruti Gajjar2, Julia Keating, M.S.3, Katherine J. Feder, MD, MS4, Sruti Ramaswamy5, Margo Brooke Gerke6, Michelle Hyunju Lee, MD7, Amir T. Fathi, MD8, Chi-Joan How, MD9, Gabriela Soriano Hobbs, MD10
1 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
2 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
5 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
6 Massachusetts General Hospital, Boston, Massachusetts, United States
7 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
8 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
9 Brigham and Women's Hospital, Boston, Massachusetts, United States
10 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States

Background: Cytoreduction is indicated for patients with polycythemia vera (PV) and essential thrombocythemia (ET) at high thrombotic risk, defined as age >60 or prior thrombosis, with JAK2 factoring in for ET patients. NCCN guidelines support cytoreduction beyond secondary prevention of thrombosis, including symptom management, bleeding risk, and resistance to phlebotomy. However, there are limited data to guide cytoreduction selection, safety and long-term efficacy in adolescent and young adult (AYA) patients, who despite often being low risk for thrombosis, may struggle with symptoms, fertility concerns and have unique risk of progression related to length of time living with an MPN. Additionally, potential for disease modification is not established as a treatment goal. Thus, we sought to characterize cytoreduction patterns in AYA patients.  

Methods: We identified AYA patients (aged 16–39 years) diagnosed with ET or PV by WHO 2022 criteria treated at Mass General Brigham (MGB) between 2007–2026 by manual chart abstraction. Data collected included disease characteristics, driver mutations, thrombosis history, symptom burden, indications for initiation and changes in cytoreductive agents. Analyses were descriptive. 

Results: 116 AYA patients were identified: 83 with ET (72%) and 33 with PV (28%). Of these, 66 (57%) were female and 90 (78%) White; median age at diagnosis was 29 years (range, 16-39). All 33 patients with PV were JAK2-mutated. Among the 83 with ET, drivers were JAK2 in 39 (47%), CALR in 36 (43%), MPL in 2 (2.4%), and triple-negative in 7 (8.4%); one patient harbored both CALR and MPL. Median follow-up was 4.4 years.  

Twenty-one (18%) patients were high-risk by prior thrombosis at the time of review; 95 (82%) were low-risk. Sixty-seven patients (58%) received cytoreduction.  

Twenty (95%) high-risk patients were cytoreduced. First-line therapy was HU in 12 (60%), IFN in 5 (25%), anagrelide in 2 (10%), and momelotinib in 1 (5.0%), though started after progression to myelofibrosis. 

Forty-seven (49%) low-risk patients received cytoreduction. Indications included inadequate blood counts with phlebotomy (n=13, 28%), symptoms (n=13, 28%), extreme thrombocytosis (>2,000 x 10⁹/L) (n=9, 19%), attempt at disease modification (n=4, 8.5%), bleeding history (n=2, 4.3%), and other (n=6, 13%). First-line therapy was HU in 24 (51%), IFN in 17 (36%), and ruxolitinib in 6 (13%). 

Of the 36 (54%) patients that received first-line HU, 28 (78%) discontinued (n=6) or switched (n=22) to second-line therapy after a median of 18.6 months (IQR, 7.9–50.5). Reasons for discontinuation or switch included intolerance/resistance in 13 (46%), attempt at disease modification in 8 (29%), symptoms in 4 (14%), and fertility concerns in 3 (11%). Seven (19%) patients remain on HU as of follow-up and one (2.8%) died while on therapy due to variceal bleeding from ET-related Budd-Chiari syndrome.  

Twenty-one patients had been prescribed HU before transferring care to MGB, and 18 (86%) discontinued (n=4) or switched (n=14) agents at the time of transfer of care. 

Of the 22 (33%) who received IFN (ropeginterferon, n=15; peginterferon, n=7) in first-line, 17 (77%) remain on therapy, 3 (14%) discontinued due to toxicity, and 2 (9.1%) switched to ruxolitinib due to symptoms. Seven (10%) patients received JAKi (ruxolitinib, n=6; momelotinib, n=1) initially; 5 (71%) remain on therapy, 1 (14%) discontinued due to anemia, and 1 (14%) switched to pacritinib in the setting of progression to myelofibrosis. 

Conclusions: In this AYA MPN cohort, a significant percentage (70%) of low-risk patients received cytoreductive therapy, highlighting the limitations of thrombosis-based criteria to guide management in this population. It is unclear if this reflects patient needs versus clinicians not following guidelines. Regardless, HU remains the most frequently used first-line agent. With increasing data of variant allele fraction reduction with interferon and ruxolitinib use, as well as unique therapy needs facing AYA patients, our data support the development of AYA-specific recommendations addressing both initiation of cytoreduction and initial agent selection, incorporating symptom burden, bleeding risk, fertility, and disease modification. 

Sandro Pino-Ascencio, MD: No relevant conflicts of interest to declare.